Aptagen, LLC
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
Peptide
VEGF-Stimulated Human Umbilical Vein Endothelial Cells (HUVECs)
Tissue
N/A nM (reported value)
In vivo mice.
N/A°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
The epitope sequence is LFPLH, from which H may function to induce tumor dormancy through inhibition of angiogenesis. See ASS peptide , which also results in suppression of tumor growth.
See also DRW peptide , which also results in suppression of tumor growth.
VEGF-Stimulated HUVECs (ID# 232)
See also DRW peptide , which also results in suppression of tumor growth.
NH2ProValValLeuPheProLeuHisCOOCOOH
8
985.29 g/mole
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Asai et al. "Isolation of a Novel Peptide Homing to Tumor-Derived Neovasculature That Suppresses Tumor Growth." Biological Pharmaceutical Bulletin, 25(2002): 904-906.
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.